Literature DB >> 22847359

Battery explantation after sacral neuromodulation in the Medicare population.

Anne P Cameron1, Jennifer T Anger, Rodger Madison, Christopher S Saigal, J Quentin Clemens.   

Abstract

AIMS: To determine sacral neuromodulation battery life and the patient and provider risk factors for early explantation in a population-based sample.
METHODS: A 5% sample of Medicare beneficiaries from 1997 to 2007 served as the data source. All patients who had a sacral neuromodulation device implanted in that time period were included. Variables included in a multivariate analysis of risk factors for removal included gender, age, race, diagnosis, type of test phase, provider specialty, and volume. The number of device reprogramming events was also recorded in this time period.
RESULTS: Mean follow-up was 60.5 months. Patients on average had 2.15 reprogramming episodes in their first year, with that number decreasing over subsequent years. Out of the 558 batteries implanted 63 (11.3%) were explanted. Of the 19 implanted individuals who carried the diagnosis of interstitial cystitis (IC), 11 (57.9%) had the battery removed. This was the only variable that predicted early removal, with an odds ratio of explantation of 10.5 (95% CI: 3.9-28.4).
CONCLUSION: Very few sacral neuromodulation batteries, once implanted, are removed prematurely. Patients with IC, however, are at very high risk of requiring premature battery removal.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22847359      PMCID: PMC4158824          DOI: 10.1002/nau.22294

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  13 in total

1.  Complications and troubleshooting of two-stage sacral neuromodulation therapy: a single-institution experience.

Authors:  Adonis Hijaz; Sandip P Vasavada; Firouz Daneshgari; Hasan Frinjari; Howard Goldman; Raymond Rackley
Journal:  Urology       Date:  2006-09-18       Impact factor: 2.649

2.  Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study.

Authors:  A C van Voskuilen; D J A J Oerlemans; E H J Weil; R A de Bie; Ph E V A van Kerrebroeck
Journal:  Eur Urol       Date:  2006-01-04       Impact factor: 20.096

Review 3.  How does sacral modulation work best? Placement and programming techniques to maximize efficacy.

Authors:  Bastian Amend; Mahmoud Khalil; Thomas M Kessler; Karl-Dietrich Sievert
Journal:  Curr Urol Rep       Date:  2011-10       Impact factor: 3.092

4.  Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study.

Authors:  Craig V Comiter
Journal:  J Urol       Date:  2003-04       Impact factor: 7.450

5.  Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention.

Authors:  S W Siegel; F Catanzaro; H E Dijkema; M M Elhilali; C J Fowler; J B Gajewski; M M Hassouna; R A Janknegt; U Jonas; P E van Kerrebroeck; A A Lycklama a Nijeholt; K A Oleson; R A Schmidt
Journal:  Urology       Date:  2000-12-04       Impact factor: 2.649

6.  Long-term effectiveness of sacral nerve stimulation for refractory urge incontinence.

Authors:  R A Janknegt; M M Hassouna; S W Siegel; R A Schmidt; J B Gajewski; D A Rivas; M M Elhilali; D C Milam; P E van Kerrebroeck; H E Dijkema; A A Lycklama à Nÿeholt; M Fall; U Jonas; F Catanzaro; C J Fowler; K A Oleson
Journal:  Eur Urol       Date:  2001-01       Impact factor: 20.096

7.  Sacral nerve stimulation for voiding dysfunction: One institution's 11-year experience.

Authors:  Suzette E Sutherland; Ann Lavers; Angeline Carlson; Cindy Holtz; Jyothi Kesha; Steven W Siegel
Journal:  Neurourol Urodyn       Date:  2007       Impact factor: 2.696

8.  Short-term results of bilateral S2-S4 sacral neuromodulation for the treatment of refractory interstitial cystitis, painful bladder syndrome, and chronic pelvic pain.

Authors:  Nasim Zabihi; Arthur Mourtzinos; Mary Grey Maher; Shlomo Raz; Larissa V Rodríguez
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-10-10

9.  Long-term outcomes of urgency-frequency syndrome due to painful bladder syndrome treated with sacral neuromodulation and analysis of failures.

Authors:  Charles R Powell; Karl J Kreder
Journal:  J Urol       Date:  2010-01       Impact factor: 7.450

10.  Incidence and predictors of complications with sacral neuromodulation.

Authors:  Wesley M White; Joe D Mobley; Regula Doggweiler; Cindy Dobmeyer-Dittrich; Frederick A Klein
Journal:  Urology       Date:  2009-02-04       Impact factor: 2.649

View more
  12 in total

1.  CUA guideline on adult overactive bladder.

Authors:  Jacques Corcos; Mikolaj Przydacz; Lysanne Campeau; Gary Gray; Duane Hickling; Christiane Honeine; Sidney B Radomski; Lynn Stothers; Adrian Wagg; Frcp Lond
Journal:  Can Urol Assoc J       Date:  2017-05-09       Impact factor: 1.862

2.  Women's perspective: intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment.

Authors:  Pooja Balchandra; Lynne Rogerson
Journal:  Int Urogynecol J       Date:  2014-03-15       Impact factor: 2.894

Review 3.  Report and Research Agenda of the American Geriatrics Society and National Institute on Aging Bedside-to-Bench Conference on Urinary Incontinence in Older Adults: A Translational Research Agenda for a Complex Geriatric Syndrome.

Authors:  Camille P Vaughan; Alayne D Markland; Phillip P Smith; Kathryn L Burgio; George A Kuchel
Journal:  J Am Geriatr Soc       Date:  2017-12-04       Impact factor: 5.562

4.  Trends and Clinical Practice Patterns of Sacral Neuromodulation for Overactive Bladder.

Authors:  Dean S Elterman; Bilal Chughtai; Emily Vertosick; Dominique Thomas; James Eastham; Jaspreet Sandhu
Journal:  Female Pelvic Med Reconstr Surg       Date:  2018 Jul/Aug       Impact factor: 2.091

5.  Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.

Authors:  Cindy L Amundsen; Yuko M Komesu; Christopher Chermansky; W Thomas Gregory; Deborah L Myers; Emily F Honeycutt; Sandip P Vasavada; John N Nguyen; Tracey S Wilson; Heidi S Harvie; Dennis Wallace
Journal:  Eur Urol       Date:  2018-02-24       Impact factor: 20.096

6.  Predictive Factors in Sacral Neuromodulation: A Systematic Review.

Authors:  Ranjana Jairam; Jamie Drossaerts; Tom Marcelissen; Gommert van Koeveringe; Desiree Vrijens; Philip van Kerrebroeck
Journal:  Urol Int       Date:  2021-05-31       Impact factor: 1.934

Review 7.  Overactive bladder - 18 years - Part II.

Authors:  Jose Carlos Truzzi; Cristiano Mendes Gomes; Carlos A Bezerra; Ivan Mauricio Plata; Jose Campos; Gustavo Luis Garrido; Fernando G Almeida; Marcio Augusto Averbeck; Alexandre Fornari; Anibal Salazar; Arturo Dell'Oro; Caio Cintra; Carlos Alberto Ricetto Sacomani; Juan Pablo Tapia; Eduardo Brambila; Emilio Miguel Longo; Flavio Trigo Rocha; Francisco Coutinho; Gabriel Favre; Jose Antonio Garcia; Juan Castano; Miguel Reyes; Rodrigo Eugenio Leyton; Ruiter Silva Ferreira; Sergio Duran; Vanda Lopez; Ricardo Reges
Journal:  Int Braz J Urol       Date:  2016 Mar-Apr       Impact factor: 1.541

8.  Predictors of implantable pulse generator placement after sacral neuromodulation: who does better?

Authors:  Jennifer T Anger; Anne P Cameron; Rodger Madison; Christopher Saigal; J Quentin Clemens
Journal:  Neuromodulation       Date:  2013-09-18

9.  Intermediate-term results of a prospective, multicenter study on remote programming sacral neuromodulation for refractory overactive bladder.

Authors:  Yaoguang Zhang; Lingfeng Meng; Peng Zhang; Xiaojun Tian; Guoqing Chen; Yan Li; Yong Zhang; Zhihui Xu; Zhongqing Wei; Wei Zhang; Lulin Ma; Benkang Shi; Limin Liao; Jianye Wang
Journal:  Transl Androl Urol       Date:  2021-05

Review 10.  Programming Algorithms for Sacral Neuromodulation: Clinical Practice and Evidence-Recommendations for Day-to-Day Practice.

Authors:  Paul A Lehur; Michael Sørensen; Thomas C Dudding; Charles H Knowles; Stefan de Wachter; Stefan Engelberg; Klaus E Matzel
Journal:  Neuromodulation       Date:  2020-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.